Vitiligo

GSK Announces Extension of FDA Review Period for Momelotinib After all, GSK will not hear from the FDA this month about its marketing application for momelotinib as a therapy for anemia in myelofibrosis patients. The pharmaceutical company announced that the US Food and Drug Administration has extended the drug'...

FDA Approves Incyte’s Opzelura as First Vitiligo Therapy The US Food and Drug Administration has approved Incyte’s Opzelura cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age and older. With this approval, Opzelura is the first and only FDA-approved...

Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age. The onset of this disease occurs between the ages of 10 and 30.  In this condition, patients progressively lose their skin color, mostly in patches. The patches ...